We are live on ! Find out more
INO icon

Inovio Pharmaceuticals
INO

98 hedge funds and large institutions have $49.5M invested in Inovio Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 20

35% more call options, than puts

Call options by funds: $1.71M | Put options by funds: $1.27M

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

2% more funds holding

Funds holding: 96 → 98 (+2)

1.9% more ownership

Funds ownership: 31.1% → 33% (+1.9%)

24% less capital invested

Capital invested by funds: $65.1M → $49.5M (-$15.6M)

Holders
98
Holders Change
+2
Holders Change %
+2.08%
% of All Funds
1.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
27
Reduced
20
Closed
16
Calls
$1.71M
Puts
$1.27M
Net Calls
+$441K
Net Calls Change
-$506K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.78M
2
BlackRock
BlackRock
New York
+$1.48M
3
Northern Trust
Northern Trust
Illinois
+$1.19M
4
GC
GMT Capital
Georgia
+$1.04M
5
DM
Deerfield Management
New York
+$631K

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$2.16M
2
Renaissance Technologies
Renaissance Technologies
New York
-$656K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$558K
4
AGM
Alpine Global Management
New York
-$201K
5
CIC
Cornercap Investment Counsel
Georgia
-$184K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
51
Ameritas Investment Partners
Nebraska
$14.4K – – –
Legal & General Group
52
Legal & General Group
United Kingdom
$12.7K – – –
TRCT
53
Tower Research Capital (TRC)
New York
$11.5K -$32.1K -3,892 -66%
SPIA
54
Steward Partners Investment Advisory
New York
$10.8K -$429 -52 -3%
California State Teachers Retirement System (CalSTRS)
55
California State Teachers Retirement System (CalSTRS)
California
$10.6K – – –
Russell Investments Group
56
Russell Investments Group
United Kingdom
$10K – – –
AWM
57
Activest Wealth Management
Florida
$8.67K – – –
NC
58
nVerses Capital
Florida
$5.78K +$8.25K +1,000 New
AB
59
Amalgamated Bank
New York
$5K – – –
CA
60
Clearstead Advisors
Ohio
$3.18K – – –
VNA
61
Valley National Advisers
Pennsylvania
$3K – – –
PNC Financial Services Group
62
PNC Financial Services Group
Pennsylvania
$2.6K – – –
FDCDDQ
63
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.54K – – –
NFSG
64
Newbridge Financial Services Group
Florida
$1.93K – – –
AF
65
Allworth Financial
California
$1.65K +$33 +4 +1%
Jones Financial Companies
66
Jones Financial Companies
Missouri
$1.36K +$206 +25 +12%
ANBT
67
American National Bank & Trust
Texas
$1.16K – – –
EWA
68
EverSource Wealth Advisors
Alabama
$1.1K – – –
CSB
69
City State Bank
Iowa
$1.06K – – –
PS
70
Principal Securities
Iowa
$1.02K +$1.13K +137 +343%
C
71
Covestor
United Kingdom
$1K -$157 -19 -7%
US Bancorp
72
US Bancorp
Minnesota
$838 – – –
LFG
73
Larson Financial Group
Missouri
$526 +$685 +83 +1,038%
BCM
74
Blume Capital Management
California
$480 – – –
CPA
75
Capital Performance Advisors
California
$480 +$685 +83 New
1 2
3
4 5

INO Hedge Fund Activity: Q3 2024 in Review

98 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2024, worth a combined $49.5M — down 24% from $65.1M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new INO positions and 16 closed out — a net gain of 4 holders — while 27 added to existing stakes and 20 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.78M. The largest seller was Deep Track Capital, cutting an estimated $2.16M.

  • 98 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2024, up from 96 in Q2 2024.
  • Funds reported $49.5M of Inovio Pharmaceuticals stock for Q3 2024, down 24% quarter-over-quarter.
  • 20 funds opened new Inovio Pharmaceuticals positions in Q3 2024 and 16 closed out, a net change of +4 holders.
  • The largest Inovio Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $1.78M added.
  • The largest Inovio Pharmaceuticals seller in Q3 2024 was Deep Track Capital, an estimated $2.16M sold.

Based on aggregated 13F filings for Q3 2024.